Main content
Eighth Celebration of Technology and Innovation honors entrepreneurs

Media Contact

Holly Korschun

WHAT: Eighth Annual Celebration of Technology and Innovation, Program and Reception

WHEN: Thursday, March 6, 2014, 4:30 p.m.

WHERE: Emory Conference Center, Silver Bell Pavilion, 1615 Clifton Rd., Atlanta, GA 30322

RSVP: Ashley Myers:, 404-727-1785


Start-up of 2013: Neurotrack
Stuart Zola, PhD, and Cecelia Manzanares (Yerkes)
Eugene Agichtein, PhD, and Dmitry Lagun, MS (math & computer science)

Neurotrack is an early-stage company that has developed computer-based tools for memory testing and behavioral assessment. The tools identify those at risk of Alzheimer’s disease or mild cognitive impairment well in advance of clinical disease diagnoses.

Stuart Zola, PhD
Stuart Zola

Deal of 2013: QUE Oncology
Dennis Liotta, PhD and Jim Snyder, PhD (chemistry)
Hyunsuk Shim, PhD (radiology)
Mary Galinski, PhD (infectious diseases & global health)

QUE Oncology, headquartered in Atlanta, is focused on the development of drugs to treat cancer and its consequences. As a joint venture between Emory University and UniQuest (Queensland, Australia), QUE Oncology has licensed two technologies from Emory, one that targets prostate cancer and one that targets breast cancer risk and hot flashes associated with estrogen hormone therapy.

Dennis Liotta, PhD
Dennis Liotta

Innovation of 2013: RSV Vaccine Technology
Martin Moore, PhD (pediatrics)

RSV (respiratory syncytial virus) is a major cause of lower respiratory tract infections in infants, children and the elderly. Vaccine development has been challenging and currently no RSV vaccine exists. Dr. Moore and his colleagues have used an alternative strategy to develop a vaccine focused on mutating certain genes of the virus to create a stable, live-attenuated RSV strain. This new recombinant RSV strain serves as a promising vaccine candidate currently being tested against RSV.

Martin Moore, PhD
Martin Moore

Emory Office of Technology Transfer (OTT)

The Emory OTT maintains a robust product pipeline, with one of the nation’s leading programs for guiding technology developed in the laboratory through the patenting and licensing process to the marketplace and into the hands of consumers and patients.

Emory currently manages more than 1,000 technologies invented by its scientists and physicians. This has led to the formation of 69 new companies and the introduction of more than 37 new products to market, some of which, like the discovery of several HIV drugs, have had major health and societal impact. Royalties earned from sales of new products by Emory licensees have resulted in more than $806 million that has subsidized additional Emory scientific research and educatio

Recent News